Dirk Haasner, Ph.D., M.P.M, is currently our senior vice president, global regulatory affairs and manufacturing. Dr. Haasner previously served as our vice president, global regulatory affairs from December 2015 to March 2016. Prior to joining us, Dr. Haasner was vice president regulatory and medical affairs, and vice president regulatory strategy and policy at Lundbeck USA, Inc., a H. Lundbeck A/S subsidiary, from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds in psychiatry and neurology. From 1994 to 2002, Dr. Haasner was employed at F. Hoffmann-La Roche AG, a publicly held healthcare company, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed global life-cycle leader. Dr. Haasner co-founded the biotech start-up 4-Antibody AG that was acquired in 2014 by Agenus Inc., a publicly held biotechnology company. Dr. Haasner obtained a M.Sc. in molecular biology at the University of Basel, Switzerland, a Ph.D. in cell biology and immunology at the Basel Institute for Immunology, and holds a postgraduate degree in pharmaceutical medicine from the EUCOR Universities Basel, Strasbourg and Freiburg.

pharmaceutical medicine